ZBHZimmer Biomet Holdings Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Bryan C. Hanson

Location

Indiana, USA

Exchange

NYSE

Website

https://zimmerbiomet.com

Summary

Zimmer Biomet Holdings, Inc.

Company Info

CEO

Bryan C. Hanson

Location

Indiana, USA

Exchange

NYSE

Website

https://zimmerbiomet.com

Summary

Zimmer Biomet Holdings, Inc.

AI Insights for ZBH
5 min read

Quick Summary

Zimmer Biomet Holdings Inc. is a U.S.-based medical technology company headquartered in Warsaw, Indiana. The company operates in the musculoskeletal healthcare market and designs, manufactures, and markets orthopedic reconstruction products, surgical technologies, sports medicine products, biologics, trauma products, foot and ankle solutions, extremity products, and dental-related offerings. Its core customers are orthopedic surgeons, hospitals, ambulatory surgery centers, healthcare systems, distributors, and patients who need joint repair, joint replacement, or mobility-restoring procedures. Zimmer Biomet is especially known for hip and knee replacement implants, where demand is supported by aging populations, osteoarthritis, sports injuries, and the growing desire for restored mobility. The company also invests in robotics, navigation, artificial intelligence, and digital surgical planning tools to make orthopedic procedures more precise and efficient.

Strengths

•

Zimmer Biomet has a strong position in the orthopedic reconstruction market, especially in knees and hips.

•

The company benefits from long-standing surgeon relationships, broad hospital access, established brands, and a large installed base of products and instruments.

•

Its business is supported by durable demographic demand because aging populations and osteoarthritis create persistent need for joint replacement and mobility-restoring procedures.

•

The company is strengthening its technology profile through robotics, AI, navigation, and digital surgery, including the ROSA platform and Monogram Technologies acquisition.

•

Zimmer Biomet also has relatively low market beta at about 0.485, which may make the stock less volatile than the broader market during some periods.

Key Risks

•

Zimmer Biomet faces risks from pricing pressure, reimbursement changes, hospital budget constraints, and competition from other major medical device companies.

•

Product launch delays, integration challenges from acquisitions, or slower-than-expected adoption of robotics could reduce investor confidence.

•

The orthopedic device market is also exposed to regulatory scrutiny, product quality requirements, recalls, litigation, and clinical outcome expectations.

•

If procedure volumes weaken due to macroeconomic stress, hospital capacity issues, labor shortages, or patient deferrals, revenue growth could slow.

What to Watch

The most recent reported dataset identifies Zimmer Biomet’s period as 2026 Q3, with total revenue of about $2.177 billion, gross profit of about $1.542 billion, operating income of about $326.1 million, and net income of about $198.3 million.
During the recent news cycle, the company highlighted innovation in orthopedic robotics, including FDA-cleared mBos TKA technology and AI-driven surgical capabilities.
Zimmer Biomet completed the acquisition of Monogram Technologies, adding semi-autonomous and fully autonomous orthopedic robotics assets to its portfolio.
The company also launched the You’ll Be Back joint-health campaign with Arnold Schwarzenegger to encourage people with joint pain and mobility issues to seek care.
Management commentary remained cautious, and investors continued to weigh strong orthopedic demand against pricing pressure, reimbursement risk, competition, and execution challenges.

Price Drivers

•

Zimmer Biomet’s stock price is driven by earnings performance, procedure volume trends, revenue growth in knees and hips, margin improvement, and management guidance.

•

The company recently beat quarterly expectations with adjusted EPS of $2.31 and revenue of $2.02 billion, but shares declined after 2025 EPS guidance of $8.15 to $8.35 came in below consensus expectations.

•

Valuation is also influenced by metrics such as a price-to-earnings ratio around 23.3, EV-to-EBITDA around 11.1, price-to-book value around 1.49, and an earnings yield around 4.29%.

•

Investor sentiment is affected by demand from aging populations and osteoarthritis patients, but also by pricing pressure, reimbursement constraints, and competition from Stryker, Smith & Nephew, DePuy Synthes, and other medtech companies.

•

Robotics announcements, acquisitions, product launches, and adoption of AI-enabled surgical platforms can create upside catalysts, while cautious guidance, execution delays, or margin pressure can weigh on the stock.

Recent News

•

Zimmer Biomet recently completed its acquisition of Monogram Technologies, adding AI-driven semi-autonomous and fully autonomous orthopedic robotics capabilities to its portfolio.

•

Monogram’s FDA-cleared CT-based knee robot is expected to launch with Zimmer Biomet implants by early 2027, strengthening the company’s robotics strategy alongside ROSA.

•

The company also announced plans to acquire Paragon 28 for about $1.2 billion, which would expand its position in foot and ankle orthopedics.

•

Zimmer Biomet launched the You’ll Be Back campaign with Arnold Schwarzenegger to raise awareness about joint health and encourage people with mobility issues to seek treatment.

•

Recent commentary also noted cautious guidance, executive changes, and investor attention to projected 2028 revenue of about $9.2 billion and fair value estimates around the low $100 range.

Market Trends

•

The orthopedic market is benefiting from aging populations, increasing osteoarthritis prevalence, demand for mobility, and continued growth in joint replacement procedures.

•

The global hip replacement market is projected to expand from about $7.8 billion in 2024 to about $11.4 billion by 2033, supported by technology adoption and better access to care.

•

Robotic surgery is also a major trend, with market penetration still relatively low and long-term growth expected as hospitals adopt navigation, AI planning, and automated surgical assistance.

•

Broader musculoskeletal markets are also being shaped by minimally invasive surgery, outpatient care, 3D-printed implants, improved materials, and data-driven procedure planning.

•

At the same time, high costs, reimbursement complexity, surgeon training requirements, infection risks, revision surgeries, and hospital budget pressure remain important constraints.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on ZBH

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@democratiCrayn 9 months ago

Market report on tissue engineering and regenerative medicine landscape

Market report on tissue engineering and regenerative medicine landscape

post thumbnail

No more topics to show